Pharmaceutical and Biologics Litigation
Overview
Crowell & Moring is home to a team of patent litigators representing and advising clients in cases arising under the “Hatch-Waxman Act” and the Biologics Price Competition and Innovation Act (BPCIA). Our life sciences patent litigation group currently consists of nearly 20 intellectual property litigators who bring experience, dedication, and skill to life sciences patent litigation.
Insights
Client Alert | 3 min read | 08.02.23
Amgen v. Sanofi: Implications for ANDA and aBLA Parties
Pharmaceutical innovators typically seek broad patent protection for their discoveries in order to prevent others from exploiting not only the specific embodiments the innovator wishes to pursue commercially, but also functional equivalents. But what happens when the additional functional equivalents that the innovator seeks to protect are not expressly disclosed in the patent? The Supreme Court recently addressed this issue in Amgen v. Sanofi.
Client Alert | 3 min read | 04.07.23
Publication | 02.24.23
Firm News | 2 min read | 04.13.22
Legal 500 EMEA Ranks Crowell & Moring in 11 Practice Areas and Recognizes Seven Lawyers
Professionals
Insights
Client Alert | 3 min read | 08.02.23
Amgen v. Sanofi: Implications for ANDA and aBLA Parties
Pharmaceutical innovators typically seek broad patent protection for their discoveries in order to prevent others from exploiting not only the specific embodiments the innovator wishes to pursue commercially, but also functional equivalents. But what happens when the additional functional equivalents that the innovator seeks to protect are not expressly disclosed in the patent? The Supreme Court recently addressed this issue in Amgen v. Sanofi.
Client Alert | 3 min read | 04.07.23
Publication | 02.24.23
Firm News | 2 min read | 04.13.22
Legal 500 EMEA Ranks Crowell & Moring in 11 Practice Areas and Recognizes Seven Lawyers